Thymosin Alpha-1
Also known as: TA1, Tα1, Thymalfasin, Zadaxin
Available Suppliers & Pricing
Price-drop alert for Thymosin Alpha-1
Get an email when the lowest listed price falls below your target. No account required.
Current lowest listed price: $35.00
By setting an alert, you request catalog price-alert emails for this research-use-only product. Alerts are informational, not medical guidance. You can unsubscribe from any alert email.
Price history
Review recorded in-stock supplier catalog prices for Thymosin Alpha-1.
Summary
Thymosin Alpha-1 is a 28-amino acid immunomodulatory peptide naturally occurring in the thymus gland that has been extensively studied for its ability to enhance and restore immune function. The peptide acts through Toll-like receptors in dendritic cells, promoting T-cell differentiation and maturation, activating natural killer cells, and modulating cytokine production. With over 4,400 subjects enrolled in clinical trials across the United States, Europe, and China, Thymosin Alpha-1 has demonstrated efficacy in treating chronic hepatitis B and C, cancer immunotherapy, sepsis, COVID-19, and as a vaccine adjuvant. The synthetic form, thymalfasin (Zadaxin), has received regulatory approval in over 30 countries for conditions including hepatitis B, hepatocellular carcinoma, and malignant melanoma. However, it is not FDA-approved in the United States, though it received orphan drug designation. Clinical experience involving over 11,000 subjects across more than 30 trials demonstrates a favorable safety profile with only minor, transient side effects, primarily mild injection site reactions. The peptide is typically administered subcutaneously at doses of 0.8-6.4 mg twice weekly.
Potential Benefits
Immune System Enhancement
- T-Cell Modulation: Promotes differentiation of immature T-lymphocytes into mature CD4+ and CD8+ T-cells, essential for adaptive immunity [1][3][8]
- Natural Killer Cell Activation: Directly activates NK cells, enhancing the body's ability to recognize and destroy virus-infected and cancerous cells [1][8]
- Dendritic Cell Stimulation: Acts through TLR-2 and TLR-9 receptors to activate dendritic cells, improving antigen presentation and immune response [3][8]
- Cytokine Regulation: Induces production of IL-2, IL-10, IL-12, IFN-α, and IFN-γ while reducing pro-inflammatory cytokines (IL-1β, TNF-α) [1][8]
Viral Infection Treatment
- Hepatitis B: Meta-analysis showed thymosin alpha-1 was 3-fold superior to placebo at 12 months post-treatment (OR 2.67, 95% CI 1.25-5.68), with odds ratios of 3.71 for virological response compared to interferon alpha at 6 months post-treatment [4][5]
- COVID-19: Reduced mortality in severe cases from 30.00% to 11.11% (P=0.044) by restoring lymphocyte counts and reducing T-cell exhaustion markers [2][1]
- Hepatitis C: Combination therapy demonstrates improved sustained virological response rates [1]
Cancer Immunotherapy
- Non-Small Cell Lung Cancer: Combination with chemotherapy achieved 33% response rate versus 10% for chemotherapy alone, while preventing chemotherapy-induced lymphopenia [6][9]
- Hepatocellular Carcinoma: Combination with lenvatinib plus sintilimab significantly improved objective response rate and prolonged overall survival and progression-free survival [6]
- Melanoma: FDA-approved as orphan drug for malignant melanoma; demonstrates immune priming and maintenance effects [1][6]
- General Anti-tumor Effects: Improved immunological parameters, increased tumor response rates, and enhanced survival and quality of life in over 1,000 cancer patients [1][6]
Sepsis Management
- Mortality Reduction: ETASS trial showed 28-day mortality decreased from 35.0% to 26.0% (RR 0.74, 95% CI 0.54-1.02) in severe sepsis patients [10]
- Meta-analysis Results: Systematic review of 12 trials demonstrated significant reduction in all-cause mortality (pooled RR 0.68, 95% CI 0.59-0.78, p<0.00001) [10]
- Immune Function Restoration: Greater improvement in monocyte HLA-DR expression on days 3 and 7 compared to controls [10]
Vaccine Enhancement
- Influenza Vaccine Adjuvant: In elderly populations, reduced influenza incidence from 19% to 6% when combined with vaccine (p=0.002) [11][12]
- Hemodialysis Patients: Enhanced immunogenicity of pandemic H1N1 vaccine in immunocompromised patients, achieving full regulatory compliance criteria [12]
- Improved Antibody Response: Both 3.2 mg and 6.4 mg doses showed better geometric mean titers and ratios compared to vaccine alone [12]
Safety Information
Clinical Safety Profile
Thymosin Alpha-1 has demonstrated an excellent safety record across extensive clinical use. A comprehensive review of over 11,000 human subjects in more than 30 clinical trials concluded that Tα1 emerges as a well-tolerated and effective immune modulator [7]. During clinical experience involving over 2,000 individuals with various diseases across all age groups, no clinically significant adverse reactions attributable to thymosin alpha-1 administration were reported [1][7].
Regulatory Status
- International Approval: Thymalfasin (Zadaxin) is approved in China and over 30 other countries for hepatitis B, hepatocellular carcinoma, and malignant melanoma [1]
- FDA Status: Not approved in the United States, though it received orphan drug designation for several conditions. The FDA explicitly stated in 2023 that TA1 does not meet legal conditions for compounding [1]
- Clinical Use: Despite lack of US approval, extensively used internationally with decades of clinical data supporting safety [9]
Side Effects
Adverse experiences have been infrequent and mild throughout clinical trials:
- Injection Site Reactions: Most common side effect consists of transient local discomfort, swelling, redness, or pain at the subcutaneous injection site [1][7]
- Rare Reactions: Occasional reports of erythema, transient muscle atrophy at injection site, polyarthralgia combined with hand edema, and rash [1]
- Systemic Effects: Infrequent reports of mild fever, fatigue, and muscle aches that resolve without intervention [1]
- No Serious Adverse Events: No serious adverse events related to thymosin alpha-1 were documented across major clinical trials [7][12]
Long-term Safety
- Low Toxicity Risk: Thymosin-alpha 1 has a low risk of toxicity and is not associated with harmful long-term side effects [1]
- Extended Use: Long-term use does not cause significant side effects, making it suitable for chronic conditions [1]
- No Laboratory Abnormalities: Does not adversely affect hematology or blood chemistry values [11][12]
Contraindications and Precautions
- Hypersensitivity: Contraindicated in patients with known hypersensitivity to thymosin alpha-1 [1]
- Immunosuppressed Patients: Use with caution in organ transplant recipients on immunosuppressive therapy, as immune enhancement may conflict with immunosuppression goals [1]
- Pregnancy and Lactation: Limited data available; use only if clearly needed [1]
Research Gaps
While safety data is robust, several areas require additional investigation:
- Optimal Dosing: While 0.8-6.4 mg twice weekly is standard, dose-optimization studies for specific conditions are limited
- Long-term Efficacy: Most trials evaluated short to medium-term outcomes; multi-year safety studies would strengthen the evidence base
- Combination Therapies: More research needed on interactions with checkpoint inhibitors and other immunotherapies
- Pediatric Use: Safety and efficacy data in children are limited outside of DiGeorge syndrome applications
- Standardized Protocols: Need for consensus guidelines on treatment duration and monitoring parameters across different indications